Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $7.20 billion. The enterprise value is $7.33 billion.
Important Dates
The next confirmed earnings date is Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 119.66 million shares outstanding. The number of shares has increased by 16.37% in one year.
| Current Share Class | 119.66M |
| Shares Outstanding | 119.66M |
| Shares Change (YoY) | +16.37% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 117.57% |
| Float | 119.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 83.15 |
| Forward PS | 77.97 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 85.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.76
| Current Ratio | 6.76 |
| Quick Ratio | 6.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.94 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.87% |
| Return on Invested Capital (ROIC) | -44.93% |
| Return on Capital Employed (ROCE) | -49.97% |
| Revenue Per Employee | $172,165 |
| Profits Per Employee | -$1.22M |
| Employee Count | 498 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.26% in the last 52 weeks. The beta is 0.68, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +17.26% |
| 50-Day Moving Average | 51.10 |
| 200-Day Moving Average | 42.13 |
| Relative Strength Index (RSI) | 60.42 |
| Average Volume (20 Days) | 1,844,242 |
Short Selling Information
The latest short interest is 14.20 million, so 11.87% of the outstanding shares have been sold short.
| Short Interest | 14.20M |
| Short Previous Month | 14.11M |
| Short % of Shares Out | 11.87% |
| Short % of Float | 11.92% |
| Short Ratio (days to cover) | 5.90 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $85.74 million and -$606.31 million in losses. Loss per share was -$5.12.
| Revenue | 85.74M |
| Gross Profit | -304.90M |
| Operating Income | -546.98M |
| Pretax Income | -606.31M |
| Net Income | -606.31M |
| EBITDA | -537.60M |
| EBIT | -546.98M |
| Loss Per Share | -$5.12 |
Full Income StatementBalance Sheet
The company has $858.14 million in cash and $991.76 million in debt, giving a net cash position of -$133.62 million or -$1.12 per share.
| Cash & Cash Equivalents | 858.14M |
| Total Debt | 991.76M |
| Net Cash | -133.62M |
| Net Cash Per Share | -$1.12 |
| Equity (Book Value) | -368.72M |
| Book Value Per Share | -3.08 |
| Working Capital | 755.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$426.92 million and capital expenditures -$11.80 million, giving a free cash flow of -$438.72 million.
| Operating Cash Flow | -426.92M |
| Capital Expenditures | -11.80M |
| Free Cash Flow | -438.72M |
| FCF Per Share | -$3.67 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -637.96% |
| Pretax Margin | -707.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.37% |
| Shareholder Yield | -16.37% |
| Earnings Yield | -8.42% |
| FCF Yield | -6.09% |
Dividend DetailsAnalyst Forecast
The average price target for Cytokinetics is $76.73, which is 27.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $76.73 |
| Price Target Difference | 27.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 143.36% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -1.99 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.99 |
| Piotroski F-Score | 3 |
